Cargando…
Recent progress and challenges in drug development against COVID-19 coronavirus (SARS-CoV-2) - an update on the status
Coronaviruses are a large group of viruses known to cause illnesses that vary between the common cold and more severe diseases to include severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS). A novel coronavirus was identified in December 2019 in Wuhan city, Hubei pro...
Autores principales: | Abd El-Aziz, Tarek Mohamed, Stockand, James D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Science
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7166307/ https://www.ncbi.nlm.nih.gov/pubmed/32320825 http://dx.doi.org/10.1016/j.meegid.2020.104327 |
Ejemplares similares
-
Marine Brominated Tyrosine Alkaloids as Promising Inhibitors of SARS-CoV-2
por: El-Demerdash, Amr, et al.
Publicado: (2021) -
Comprehensive Virtual Screening of the Antiviral Potentialities of Marine Polycyclic Guanidine Alkaloids against SARS-CoV-2 (COVID-19)
por: El-Demerdash, Amr, et al.
Publicado: (2021) -
Snake Venoms in Drug Discovery: Valuable Therapeutic Tools for Life Saving
por: Mohamed Abd El-Aziz, Tarek, et al.
Publicado: (2019) -
Human recombinant soluble ACE2 (hrsACE2) shows promise for treating severe COVID19
por: Abd El-Aziz, Tarek Mohamed, et al.
Publicado: (2020) -
Optogenetic Control of PIP2 Interactions Shaping ENaC Activity
por: Abd El-Aziz, Tarek Mohamed, et al.
Publicado: (2022)